These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 14576660)

  • 21. A controlled Phase II trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir and efavirenz in non-nucleoside reverse transcriptase inhibitor-naive HIV-infected adults.
    Lalezari JP; DeJesus E; Northfelt DW; Richmond G; Wolfe P; Haubrich R; Henry D; Powderly W; Becker S; Thompson M; Valentine F; Wright D; Carlson M; Riddler S; Haas FF; DeMasi R; Sista PR; Salgo M; Delehanty J
    Antivir Ther; 2003 Aug; 8(4):279-87. PubMed ID: 14518696
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A novel form of amyloid deposited at the site of enfuvirtide injection.
    Naujokas A; Vidal CI; Mercer SE; Harp J; Kurtin PJ; Fox LP; Thompson MM
    J Cutan Pathol; 2012 Feb; 39(2):220-1; quiz 219. PubMed ID: 22264247
    [No Abstract]   [Full Text] [Related]  

  • 23. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia.
    Lazzarin A; Clotet B; Cooper D; Reynes J; Arastéh K; Nelson M; Katlama C; Stellbrink HJ; Delfraissy JF; Lange J; Huson L; DeMasi R; Wat C; Delehanty J; Drobnes C; Salgo M;
    N Engl J Med; 2003 May; 348(22):2186-95. PubMed ID: 12773645
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enfuvirtide.
    Dando TM; Perry CM
    Drugs; 2003; 63(24):2755-66; discussion 2767-8. PubMed ID: 14664654
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A delayed hypersensitivity reaction to enfuvirtide after rechallenge.
    Emerson CR; Post JJ; Workman C
    Int J STD AIDS; 2009 Apr; 20(4):288-9. PubMed ID: 19304981
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of switching from enfuvirtide to raltegravir in patients with virological suppression.
    Santos JR; Llibre JM; Ferrer E; Domingo P; Imaz A; Moltó J; Martin-Iguacel R; Caum C; Podzamczer D; Clotet B
    HIV Clin Trials; 2009; 10(6):432-8. PubMed ID: 20133273
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HIV-1 gp41 heptad repeat 2 (HR2) possesses an amino acid domain that resembles the allergen domain in Aspergillus fumigatus Asp f1 protein: review, hypothesis and implications.
    Becker Y
    Virus Genes; 2007 Jun; 34(3):233-40. PubMed ID: 17333401
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enfuvirtide: a novel agent for the treatment of HIV-1 infection.
    Duffalo ML; James CW
    Ann Pharmacother; 2003 Oct; 37(10):1448-56. PubMed ID: 14519027
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of education and support on the tolerability and quality of life in a cohort of HIV-1 infected patients treated with enfuvirtide (SURCOUF Study).
    Allavena C; Prazuck T; Reliquet V; Verdon R; Perré P; Le Moal G; Billaud E; Raffi F
    J Int Assoc Physicians AIDS Care (Chic); 2008; 7(4):187-92. PubMed ID: 18599881
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Enfuvirtide: the first step for a new strategy of antiretroviral therapy].
    Bottaro EG
    Medicina (B Aires); 2007; 67(2):195-205. PubMed ID: 17593608
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Successful desensitization to enfuvirtide after a hypersensitivity reaction in an HIV-1-infected man.
    DeSimone JA; Ojha A; Pathak R; Cohn J
    Clin Infect Dis; 2004 Nov; 39(10):e110-2. PubMed ID: 15546072
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Successful long-course after failure of short-course desensitization in a patient with severe hypersensitivity reaction to enfuvirtide.
    Quiros-Roldan E; Tirelli V; Torti C; Sosta E; Tosoni C; Damiolini E; Carosi G
    AIDS; 2007 Jun; 21(10):1388-9. PubMed ID: 17545726
    [No Abstract]   [Full Text] [Related]  

  • 33. Postmarketing use of enfuvirtide in veterans: provider compliance with criteria for use, overall efficacy, and tolerability.
    Belperio PS; Mole LA; Halloran J; Boothroyd DB; Thomas IC; Backus LI
    Ann Pharmacother; 2008 Nov; 42(11):1573-80. PubMed ID: 18940919
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Enfuvirtide: a review of its use in the management of HIV infection.
    Oldfield V; Keating GM; Plosker G
    Drugs; 2005; 65(8):1139-60. PubMed ID: 15907147
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A report on the effect of commencing enfuvirtide on peripheral neuropathy.
    Cherry CL; Duncan AJ; Mackie KF; Wesselingh SL; Brew BJ
    AIDS Res Hum Retroviruses; 2008 Aug; 24(8):1027-30. PubMed ID: 18724802
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Enfuvirtide (T-20): a novel human immunodeficiency virus type 1 fusion inhibitor.
    Cervia JS; Smith MA
    Clin Infect Dis; 2003 Oct; 37(8):1102-6. PubMed ID: 14523775
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The safety and efficacy of enfuvirtide therapy for HIV infection in patients with hemophilia: a case series.
    Polizzotto MN; Street AM; Wright E
    Clin Infect Dis; 2007 Aug; 45(4):e39-41. PubMed ID: 17638184
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Switching from a toxicity-causing antiretroviral to enfuvirtide in patients with HIV: the SWITCH TOX study.
    Streinu-Cercel A; de Gorgolas M; Müller M; Portilla J; Rugina S; Böcher W; Staszewski S; Pulik P; Rowell L; Salgo M; Stoll M
    HIV Clin Trials; 2008; 9(6):375-86. PubMed ID: 19203903
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enfuvirtide (Fuzeon).
    Proj Inf Perspect; 2003 Oct; (36):4-5. PubMed ID: 14696566
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults.
    Kilby JM; Lalezari JP; Eron JJ; Carlson M; Cohen C; Arduino RC; Goodgame JC; Gallant JE; Volberding P; Murphy RL; Valentine F; Saag MS; Nelson EL; Sista PR; Dusek A
    AIDS Res Hum Retroviruses; 2002 Jul; 18(10):685-93. PubMed ID: 12167274
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.